exhibit index exhibit no. description

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): SEPTEMBER 12, 2016 (SEPTEMBER 12, 2016)

MOLECULIN BIOTECH, INC.(Exact Name of Registrant as Specified in its Charter)

DELAWARE 001-37758 47-4671997

(State or Other Jurisdiction of Incorporationor Organization)

(Commission File No.) (I.R.S. Employer Identification No.)

2575 WEST BELLFORT, SUITE 333, HOUSTON TX 77054

(Address of principal executive offices and zip code)

(713) 300-5160(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant underany of the following provisions (see General Instruction A.2. below): ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).

Item 7.01. Regulation FD Disclosure.

On September 13, 2016 at 12:05 p.m. (Eastern Time), Moleculin Biotech, Inc. (the “Company”) will be featured as a presenting

company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.Representatives of the Company will use the presentation set forth as Exhibit 99.1 herein in connection with the foregoing presentation andin various meetings with investors from time to time.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall

not be deemed to be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be deemedincorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identifiedtherein as being incorporated by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description99.1 Moleculin Biotech, Inc. Investor Presentation

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed onits behalf by the undersigned hereunto duly authorized.

MOLECULIN BIOTECH, INC. Date: September 12, 2016 By: /s/ Jonathan Foster Jonathan Foster Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No. Description

99.1 Moleculin Biotech, Inc. Investor Presentation

3

Exhibit 99.1

August 2016

Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions,including those described in the “Risk Factors” section of the registration statement on Form S-1 we filed on April 27, 2016. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements.

We built Moleculin around a diverse portfolio of disruptive cancer technologies, each with high revenue potential. Our lead leukemia drug candidate has already shown life-saving potential in clinical trials. We have a unique compound that appears to both attack the most difficult cancers directly while also stimulating the patient’s natural immune response and we have a promising new approach to reaching and treating brain tumors. - Wally Klemp, Chairman

Moleculin Team

Veteran Management Team Cisplatin Carboplatin COO Harvard, Tufts, UVA Dana Farber, FDA #1 INC 500 List $400 million in revenue CMO CEO

Advisors and Board Members Reata Pharmaceuticals Big 4 audit partners Multi-billion dollar exit Cancer experts

All of our technologies were developed at MD Anderson Cancer Center, the world’s largest cancer research facility headquartered within the world’s largest medical center With over 1,500 cancer researchers, our sponsored research has been supported by truly state of the art resources

Technology Portfolio

Discovery (Finding potential new drugs) Pre-Clinical Development (Laboratory Testing) IND Filing (Investigational New Drug; FDA Filing) Phase I/II (Human safety & proof of concept) Approval Trial (Phase IIb or III as required) Adult AML WP1066 (Glioblastoma, metastatic melanoma) WP1122 (Glioblastoma) Pediatric acute leukemia WP1220 (CTCL) WP1066 (Pancreatic, other) (To be refiled) Annamycin WP1066 Portfolio WP1122 Portfolio = Potential key value inflection point Sponsored CNS malignancies Research

Annamycin

BMT (Results in Cure) 20% 80% Success Failure Induc4on Therapy (Qualify for BMT) 80% 20% Success Failure

Non-cardiotoxic Avoids multidrug resistance More potent Cardiotoxic Defeated by multidrug resistance Current Drugs Annamycin

Doxorubicin Example

Annamycin Example

Annamycin Delivers Relapsed/Refractory Acute Leukemia Patients 50% Efficacy Signal 30% Cleared Bone Marrow Blasts Annamycin gives new hope to patients who have run out of options Patients failed an average of 5 previous Induction Therapy attempts with standard of care

Annamycin (based on last trial) What is possible if we get to patients sooner?

WP1066 Directly attacks the worst cancers Recruits natural immune system IRB approved for human trial

WP1122 Cuts off fuel supply to brain tumors Outperforms billion-dollar drug Human trials in 1-2 years

We Are Excited

Investment Highlights Multiple shots Worldclass collaboration Game-changing breakthroughs Solid protection Veteran management